| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2997 | 2019 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 454 | 2021 |
| Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double … L Thamlikitkul, V Srimuninnimit, C Akewanlop, S Ithimakin, ... Supportive Care in Cancer 25, 459-464, 2017 | 82 | 2017 |
| Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial S Peters, R Dziadziuszko, A Morabito, E Felip, SM Gadgeel, P Cheema, ... Nature medicine 28 (9), 1831-1839, 2022 | 55 | 2022 |
| Clinical correlates of benefit from radium‐223 therapy in metastatic castration resistant prostate cancer A Alva, L Nordquist, S Daignault, S George, J Ramos, C Albany, ... The Prostate 77 (5), 479-488, 2017 | 46 | 2017 |
| Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 BC Cho, MJ Ahn, JH Kang, RA Soo, T Reungwetwattana, JCH Yang, ... Journal of Clinical Oncology 41 (26), 4208-4217, 2023 | 43 | 2023 |
| LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from … BC Cho, E Felip, AI Spira, N Girard, JS Lee, SH Lee, YV Ostapenko, ... Annals of Oncology 34, S1306, 2023 | 41 | 2023 |
| Successful treatment of IgG and complement‐mediated autoimmune hemolytic anemia with bortezomib and low‐dose cyclophosphamide P Danchaivijitr, J Yared, AP Rapoport American journal of hematology 86 (3), 331-332, 2011 | 27 | 2011 |
| Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced … S Ithimakin, P Theeratrakul, A Laocharoenkiat, A Nimmannit, ... Supportive Care in Cancer 28, 5335-5342, 2020 | 24 | 2020 |
| Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation J Chantharasamee, N Poungvarin, P Danchaivijitr, S Techawatanawanna BMC cancer 19, 1-9, 2019 | 19 | 2019 |
| 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m) NSCLC … R Dziadziuszko, S Peters, SM Gadgeel, MS Mathisen, SM Shagan, ... Annals of Oncology 32, S950-S951, 2021 | 16 | 2021 |
| Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a … BC Cho, E Felip, AI Spira, N Girard, JS Lee, SH Lee, YV Ostapenko, ... Annals of Oncology 34, S1306-S1306, 2023 | 14 | 2023 |
| Phase I study of dalteparin in combination with sunitinib in patients with metastatic clear cell renal carcinoma MQ Wentink, HMW Verheul, SK Pal, S George, J Voortman, ... Clinical Genitourinary Cancer 16 (1), e1-e9, 2018 | 11 | 2018 |
| Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East … E Mustafa, B Bivas, D Pongwut, C Lingwu, YF Wong, T Hashem, CS Lim, ... Bmc Cancer 21, 1-10, 2021 | 10 | 2021 |
| KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC S Ren, J Feng, S Ma, HJ Chen, Z Ma, C Huang, L Zhang, J He, C Wang, ... International Journal of Cancer 153 (3), 623-634, 2023 | 9 | 2023 |
| Efficacy of combination docetaxel and nintedanib in advanced non-small cell lung cancer in Thailand: a multicenter study K Korphaisarn, P Danchaivijitr, T Reungwetwattana, B Chewaskulyong, ... Frontiers in Oncology 11, 572740, 2021 | 6 | 2021 |
| Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand N Ngamphaiboon, A Dechaphunkul, J Setakornnukul, T Dechaphunkul, ... BMC cancer 20, 1-10, 2020 | 6 | 2020 |
| LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup … S Lu, BC Cho, JS Lee, SH Lee, P Danchaivijitr, B Liu, A Alip, H Xiong, ... Annals of Oncology 34, S1661, 2023 | 5 | 2023 |
| Lazertinib versus gefitinib tyrosine kinase inhibitors in treatment-naíve patients with EGFR-mutated advanced NSCLC: analysis of the Asian Subpopulation in LASER301 T Reungwetwattana, BC Cho, KH Lee, YK Pang, CH Fong, JH Kang, ... Journal of Thoracic Oncology 18 (10), 1351-1361, 2023 | 5 | 2023 |
| Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis RA Soo, BC Cho, JH Kim, MJ Ahn, KH Lee, A Zimina, S Orlov, ... Journal of Thoracic Oncology 18 (12), 1756-1766, 2023 | 4 | 2023 |
